GTC
KDNY

Ghost Tree Capital’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Ghost Tree Capital’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-100,000
Closed -$4.65M – 62
2018
Q1 		$4.65M Buy
+100,000
New +$3.66M 0.94% 34
2017
Q2 		– Sell
-160,000
Closed -$8.6M – 80
2017
Q1 		$8.6M Buy
+160,000
New +$9.04M 1.6% 25

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Ghost Tree Capital's KDNY Position: Q2 2018 in Review

Ghost Tree Capital sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2018, closing a stake of 100,000 shares — an estimated $4.65M sold.

Ghost Tree Capital first reported a position in KDNY in Q1 2017 and held it in 2 quarters. The position peaked at $8.6M in Q1 2017. 89 funds tracked by Wall St. Rank hold KDNY as of Q2 2018.

  • Ghost Tree Capital reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Ghost Tree Capital sold 100,000 Chinook Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $4.65M.
  • Ghost Tree Capital first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Ghost Tree Capital's Chinook Therapeutics, Inc. Common Stock position peaked at $8.6M in Q1 2017.
  • 89 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Ghost Tree Capital's 13F filing for Q2 2018, filed 14 Aug 2018.